DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
Pollet, S
Van den Enden, M
Language :
English
Title :
A multicentre, observational study on demographic and disease characteristics of patients seeking care for chronic hepatitis C in Belgium in 2016
GOWER E., ESTES C., BLACH S., RAZAVI-SHEARER K., RAZAVI H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 2014, 61:(S1): S45-57.
LANGLET P., D’HEYGERE F., HENRION J., ADLER M., DELWAIDE J., VAN VLIERBERGHE H. et al. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment naïve or relapsing chronic hepatitis C patients. Aliment. Pharmacol. Ther. 2009, 30: 352-363.
NEVENS F., VAN VLIERBERGHE H., D’HEYGERE E., DELWAIDE J., ADLER M., HENRION J. et al. A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a in combination with ribavirin in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterol. Belg. 2010, 73: 223-228.
MULKAY J.P., BOURGEOIS S., LASSER L., DE GALOCSY C., TOMASOVIC S., HORSMANS Y. et al. Characteristics, treatment and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium: a sub-analysis of the PROPHESYS study. Acta Gastroenterol. Belg. 2014, 77: 30-40.
DE GALOCSY C., KAUFMAN L., TOMASOVIC S., DELWAIDE J., NEVENS F. Hepatitis C genotype 4 response rate to pegylated interferon and ribavirin treatment in Belgium is similar to genotype 1. Acta Gastroenterol. Belg. 2010, 73: 229-234.
DELWAIDE J., REENAERS C., GERARD C., VAIRA D., BASTENS B., SERVAIS B. et al. HCV genotype 4 in Belgium: three distinct patterns among patients from European and African origin. Eur. J. Gastroenterol. Hepatol. 2006, 18: 707-712.
DE MAEGHT S., HENRION J., BOURGEOIS N., DE GALOCSY C., LANGLET P., MICHIELSEN P. et al. A pilot observational survey of hepatitis C in Belgium. Acta Gastroenterol. Belg. 2008, 71: 4-8.
RAZAVI H., WAKED I., SARRAZIN C., MYERS R.P., IDILMAN R., CALINAS F. et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J. Viral. Hep. 2014, 21(S1): 34-59.
BEDOSSA P., POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24: 289-293.
MUYLDERMANS G., VAN GUCHT S., VAN BAELEN L. Wetenschappelijk Instituut Volksgezondheid-Institut Scientifique de Santé Publique (WIV-ISP), Rapport Annuel 2016: Virus de l’Hépatite C (VHC). 2017. https://nrchm. wiv-isp.be/fr/centres_ref_labo/hepatitis_b_d_d_e_et_viruses/Rapports/ rapport%20HCV%2 02016.pdf (Last accessed on 03 July 2018)
VERBEECK J., KWANTEN L., D’HEYGERE F., BEGUIN A., MICHIELS S., DESOMBERE I. et al. HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 29: 1427-1434.
ROBAEYS G., BIELEN R., AZAR D.G., RAZAVI H., NEVENS F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. 2016, 65: 1094-1103.
OLIVEIRA A.C., BORTOTTI A.C., NUNES N.N., EL BACHA I.A., PARISE E.R. Association between age at diagnosis and degree of liver injury in hepatitis C. Braz. J. Infect. Dis. 2014, 18: 507-511.
MARSHALL A.D., CUNNINGHAM E.B., NIELSEN S., AGHEMO A., ALHO H., BACKMUND M. et al. Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018, 3: 125-133.
NEVENS F., COLLEB I., MICHIELSEN P., ROBAEYS G., MORENOE C., CAEKELBERGH K. et al. Resource use and cost of hepatitis C-related care. Eur. J. Gastroenterol. Hepatol. 2012, 24: 1191-1198.
STÄRKEL P., VANDIJCK D., LALEMAN W., VAN DAMME P., MORENO C., HINDMAN S et al. The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy. Acta. Gastroenterol. Belg. 2014, 77: 280-284.
VANDIJCK D., MORENO C., STÄRKEL P., VAN DAMME P., VAN VLIERBERGHE H., HINDMAN S.J. et al. Current and future health and economic impact of hepatitis C in Belgium. Acta. Gastroenterol. Belg. 2014, 77: 285-290.
GERKENS S., THIRY N., HULSTAERT F., ROBAYS J. Towards an expansion of the reimbursement conditions for hepatitis C therapies? – Summary. Health Technology Assessment (HTA). Brussels, Belgium: Belgian Health Care Knowledge Centre (KCE), 2016.
